High expression of HNF4A, HK2, or SLC2A1 was associated with poor survival of patients with NB, breast cancer, colon cancer, glioblastoma, lung cancer, ovarian cancer, or prostate cancer (Additional file 1: Figure S2e and Figure S3). Here, HNF4A is linked to ovarian carcinoma.